Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
金曜日, 9 04

Edwards Lifesciences Corp

EWNYSE
Trade with Public
Trade with Public
$89.78
-1.04-1.15%
近くで: Sep 2, 5:00 PM EST
$89.78
-1.04-1.15%
プレマーケット: 4:37 AM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Edwards Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edwards Lifesciences (EW).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

17Buy
3Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$100Upside to Avg. PT+11.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026UBSPatrick WoodAssumesNeutral→Buy$110
Jul 24, 2026Leerink PartnersMike KratkyUpgradeMarket Perform→Outperform$87→$101
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Benzinga Newsdesk

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Vandana Singh

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105

Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved